• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

    2/13/24 4:56:01 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email
    SC 13G/A 1 tv0169-acadiapharmaceuticals.htm SCHEDULE 13G/A acadiapharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  ACADIA Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  004225108

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  004225108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    220,637

    7.  SOLE DISPOSITIVE POWER

    13,055,348

    8.  SHARED DISPOSITIVE POWER

    340,661

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,396,009

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.16%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ACADIA Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    12830 El Camino Real, Suite 400
    San Diego, CA 92130-3331

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    004225108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ACAD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD

    DatePrice TargetRatingAnalyst
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    2/11/2025$22.00Hold
    Deutsche Bank
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    10/10/2024Mkt Perform
    Raymond James
    8/7/2024$28.00 → $20.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$31.00Outperform
    BMO Capital Markets
    3/12/2024$36.00 → $32.00Buy
    Needham
    3/12/2024$39.00 → $25.00Buy → Neutral
    Mizuho
    More analyst ratings

    $ACAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACADIA Pharmaceuticals upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded ACADIA Pharmaceuticals from Hold to Buy and set a new price target of $35.00

    5/21/25 8:39:09 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on ACADIA Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00

    2/11/25 7:00:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACADIA Pharmaceuticals downgraded by Guggenheim with a new price target

    Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously

    1/3/25 7:17:06 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 63,477 shares of common stock and 49,377 restricted stock units ("RSUs") to twenty-six new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $23.64 per share, Acadia's closing trading price on August 5, 2025, and will vest over four years, with 2

    8/11/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

    - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE® (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the second quarter ended June 30, 2025. "Acadia continued to build momentum in the second qua

    8/6/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We

    8/5/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold $554,024 worth of shares (22,000 units at $25.18), decreasing direct ownership by 35% to 40,130 units (SEC Form 4)

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    8/19/25 6:00:07 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brege Laura sold $314,634 worth of shares (14,446 units at $21.78), decreasing direct ownership by 49% to 15,095 units (SEC Form 4)

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    6/5/25 6:01:14 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Daly James M converted options into 9,387 shares, increasing direct ownership by 38% to 34,041 units (SEC Form 4)

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    6/2/25 6:05:06 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    SEC Filings

    View All

    ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

    8/6/25 4:18:59 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by ACADIA Pharmaceuticals Inc.

    8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

    6/10/25 4:06:24 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by ACADIA Pharmaceuticals Inc.

    144 - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    6/4/25 4:35:16 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    Financials

    Live finance-specific insights

    View All

    Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

    - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE® (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the second quarter ended June 30, 2025. "Acadia continued to build momentum in the second qua

    8/6/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

    Company to host conference call and webcast on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until November 5, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number

    7/23/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

    - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

    5/7/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    Leadership Updates

    Live Leadership Updates

    View All

    Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation including technology, data and AI strategy and will serve as a member of the company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "We are thrilled to welcome Scott to Acadia," said Catherine Owen Adams. "Scott's extensive leadership in digital transformation, AI-driven innovation, and global IT operations across leading biopharmaceutical companies makes him an ideal fit for our organization. His proven ability to scale digital

    8/4/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio. "We are delighted to welcome Allyson to Acadia," said Catherine Owen Adams, Chief Executive Officer. "She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology

    5/27/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group

    12/30/24 5:37:00 PM ET
    $ACAD
    $IBTX
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance

    $ACAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

    SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    11/14/24 6:48:52 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.

    SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    2/14/24 7:08:13 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    2/13/24 4:56:01 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care